Markedly elevated soluble E-cadherin in plasma of patient with pelvic inflammatory disease

Hsiu Ting Tsai, Tsung Hsien Lee, Shun Fa Yang, Long Yau Lin, Yi Torng Tee, Po Hui Wang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To estimate the expression of plasma soluble E-cadherin and the gene polymorphism in patients with pelvic inflammatory disease (PID). Design: Hospital-based case-control study. Setting: University hospital. Patient(s): Sixty-four women with PID. Intervention(s): Blood specimen collection from patients before and after they received treatment. Main Outcome Measure(s): Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were respectively used to measure the plasma soluble E-cadherin level and E-cadherin polymorphism. Result(s): The level of plasma E-cadherin was significantly elevated in patients with PID as compared with that in normal controls; it decreased significantly after treatment when compared with levels noted in the same patients before they received treatment. When the cutoff level of plasma E-cadherin level was set to 20.22 ng/mL on the basis of receiver-operating characteristic curve (ROC), the sensitivity, specificity, and the area under the curve of plasma E-cadherin level for predicting PID were 0.81, 0.80, and 0.835 (95% confidence interval 0.76-0.90), respectively. The adjusted odds ratio for age, white blood cell count, and C-reactive protein levels was 19.66 (5.48-70.47). Conclusion(s): Elevated plasma soluble E-cadherin expression was involved in the pathogenesis of PID and is useful for the diagnosis of PID.

Original languageEnglish
Pages (from-to)490-495
Number of pages6
JournalFertility and Sterility
Volume99
Issue number2
DOIs
Publication statusPublished - Feb 2013
Externally publishedYes

Fingerprint

Pelvic Inflammatory Disease
Cadherins
Blood Specimen Collection
Hospital Design and Construction
Leukocyte Count
ROC Curve
Restriction Fragment Length Polymorphisms
C-Reactive Protein
Area Under Curve
Case-Control Studies
Therapeutics
Enzyme-Linked Immunosorbent Assay
Odds Ratio
Outcome Assessment (Health Care)
Confidence Intervals
Sensitivity and Specificity
Polymerase Chain Reaction
Genes

Keywords

  • E-cadherin
  • pelvic inflammatory disease (PID)
  • single nucleotide polymorphism (SNP)

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Markedly elevated soluble E-cadherin in plasma of patient with pelvic inflammatory disease. / Tsai, Hsiu Ting; Lee, Tsung Hsien; Yang, Shun Fa; Lin, Long Yau; Tee, Yi Torng; Wang, Po Hui.

In: Fertility and Sterility, Vol. 99, No. 2, 02.2013, p. 490-495.

Research output: Contribution to journalArticle

Tsai, Hsiu Ting ; Lee, Tsung Hsien ; Yang, Shun Fa ; Lin, Long Yau ; Tee, Yi Torng ; Wang, Po Hui. / Markedly elevated soluble E-cadherin in plasma of patient with pelvic inflammatory disease. In: Fertility and Sterility. 2013 ; Vol. 99, No. 2. pp. 490-495.
@article{74352851cf0744ee81194309c448673e,
title = "Markedly elevated soluble E-cadherin in plasma of patient with pelvic inflammatory disease",
abstract = "Objective: To estimate the expression of plasma soluble E-cadherin and the gene polymorphism in patients with pelvic inflammatory disease (PID). Design: Hospital-based case-control study. Setting: University hospital. Patient(s): Sixty-four women with PID. Intervention(s): Blood specimen collection from patients before and after they received treatment. Main Outcome Measure(s): Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were respectively used to measure the plasma soluble E-cadherin level and E-cadherin polymorphism. Result(s): The level of plasma E-cadherin was significantly elevated in patients with PID as compared with that in normal controls; it decreased significantly after treatment when compared with levels noted in the same patients before they received treatment. When the cutoff level of plasma E-cadherin level was set to 20.22 ng/mL on the basis of receiver-operating characteristic curve (ROC), the sensitivity, specificity, and the area under the curve of plasma E-cadherin level for predicting PID were 0.81, 0.80, and 0.835 (95{\%} confidence interval 0.76-0.90), respectively. The adjusted odds ratio for age, white blood cell count, and C-reactive protein levels was 19.66 (5.48-70.47). Conclusion(s): Elevated plasma soluble E-cadherin expression was involved in the pathogenesis of PID and is useful for the diagnosis of PID.",
keywords = "E-cadherin, pelvic inflammatory disease (PID), single nucleotide polymorphism (SNP)",
author = "Tsai, {Hsiu Ting} and Lee, {Tsung Hsien} and Yang, {Shun Fa} and Lin, {Long Yau} and Tee, {Yi Torng} and Wang, {Po Hui}",
year = "2013",
month = "2",
doi = "10.1016/j.fertnstert.2012.10.010",
language = "English",
volume = "99",
pages = "490--495",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Markedly elevated soluble E-cadherin in plasma of patient with pelvic inflammatory disease

AU - Tsai, Hsiu Ting

AU - Lee, Tsung Hsien

AU - Yang, Shun Fa

AU - Lin, Long Yau

AU - Tee, Yi Torng

AU - Wang, Po Hui

PY - 2013/2

Y1 - 2013/2

N2 - Objective: To estimate the expression of plasma soluble E-cadherin and the gene polymorphism in patients with pelvic inflammatory disease (PID). Design: Hospital-based case-control study. Setting: University hospital. Patient(s): Sixty-four women with PID. Intervention(s): Blood specimen collection from patients before and after they received treatment. Main Outcome Measure(s): Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were respectively used to measure the plasma soluble E-cadherin level and E-cadherin polymorphism. Result(s): The level of plasma E-cadherin was significantly elevated in patients with PID as compared with that in normal controls; it decreased significantly after treatment when compared with levels noted in the same patients before they received treatment. When the cutoff level of plasma E-cadherin level was set to 20.22 ng/mL on the basis of receiver-operating characteristic curve (ROC), the sensitivity, specificity, and the area under the curve of plasma E-cadherin level for predicting PID were 0.81, 0.80, and 0.835 (95% confidence interval 0.76-0.90), respectively. The adjusted odds ratio for age, white blood cell count, and C-reactive protein levels was 19.66 (5.48-70.47). Conclusion(s): Elevated plasma soluble E-cadherin expression was involved in the pathogenesis of PID and is useful for the diagnosis of PID.

AB - Objective: To estimate the expression of plasma soluble E-cadherin and the gene polymorphism in patients with pelvic inflammatory disease (PID). Design: Hospital-based case-control study. Setting: University hospital. Patient(s): Sixty-four women with PID. Intervention(s): Blood specimen collection from patients before and after they received treatment. Main Outcome Measure(s): Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were respectively used to measure the plasma soluble E-cadherin level and E-cadherin polymorphism. Result(s): The level of plasma E-cadherin was significantly elevated in patients with PID as compared with that in normal controls; it decreased significantly after treatment when compared with levels noted in the same patients before they received treatment. When the cutoff level of plasma E-cadherin level was set to 20.22 ng/mL on the basis of receiver-operating characteristic curve (ROC), the sensitivity, specificity, and the area under the curve of plasma E-cadherin level for predicting PID were 0.81, 0.80, and 0.835 (95% confidence interval 0.76-0.90), respectively. The adjusted odds ratio for age, white blood cell count, and C-reactive protein levels was 19.66 (5.48-70.47). Conclusion(s): Elevated plasma soluble E-cadherin expression was involved in the pathogenesis of PID and is useful for the diagnosis of PID.

KW - E-cadherin

KW - pelvic inflammatory disease (PID)

KW - single nucleotide polymorphism (SNP)

UR - http://www.scopus.com/inward/record.url?scp=84873293551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873293551&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2012.10.010

DO - 10.1016/j.fertnstert.2012.10.010

M3 - Article

C2 - 23122825

AN - SCOPUS:84873293551

VL - 99

SP - 490

EP - 495

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 2

ER -